Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction

OBJECTIVE: It is unclear if activation of inflammatory pathways regulates proprotein convertase subtilisin-kexin type 9 (PCSK9) levels. APPROACH: We evaluated (1) the temporal course of serum PCSK9 during hospitalisation following acute coronary syndrome and associations with markers of inflammation...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Heart
Hlavní autoři: Ueland, Thor, Kleveland, Ola, Michelsen, Annika E, Wiseth, Rune, Damås, Jan Kristian, Aukrust, Pål, Gullestad, Lars, Halvorsen, Bente, Yndestad, Arne
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2018
Témata:
Coronary Artery Disease
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6150185/
https://ncbi.nlm.nih.gov/pubmed/30258647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2017-000765
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky